WS 11 - Falsified and Sub-Standard Medicine

Marketing and distribution of falsified and substandard medication is a global problem, endangering the appropriate treatment of patients, putting their health and life at risk. Globally, it is estimated that about ten percent of all traded medication is falsified or substandard, in some regions the situation is much worse. There is a need to detect falsified and substandard drugs and eliminate them from pharma markets to protect patients and to secure the therapy success.

This session aims at analyzing the scope of the global problem of falsified and substandard drugs, and to demonstrate and discuss practical and locally appropriate options to reduce the risk of fake and substandard drugs entering markets, and measures to detect and eliminate them.